Mediation of β-endorphin in andrographolide-induced plasma glucose-lowering action in type I diabetes-like animals

Bu Chin Yu, Cheng Kuei Chang, Chih Fen Su, Juei Tang Cheng

研究成果: 雜誌貢獻文章

39 引文 (Scopus)

摘要

In the present study, we investigated the mechanism(s) for glucose-lowering action of andrographolide in streptozotocin-induced diabetic rats (STZ-diabetic rats). Andrographolide lowered plasma glucose concentrations in a dose-dependent manner and increased plasma β-endorphin-like immunoreactivity (BER) dose-dependently in diabetic rats. Both of these responses to andrographolide were abolished by the pretreatment of animals with prazosin or N-(2 -(2-cyclopropylmethoxy) ethyl) 5-choro-α-dimethyl-1H- indole-3-thylamine (RS17053) at doses sufficient to block α1- adrenoceptors (ARs). Also, andrographolide enhanced BER release from isolated rat adrenal medulla in a concentration-related manner that could be abolished by α1-ARs antagonists. Bilateral adrenalectomy in STZ-diabetic rats eliminated the activities of andrographolide, including the plasma glucose-lowering effect and the plasma BER-elevating effect. Andrographolide failed to lower plasma glucose in the presence of opioid μ-receptor antagonists and in the opioid μ-receptor knockout diabetic mice. Treatment of STZ-diabetic rats with andrographolide resulted in the reduced expression of phosphoenolpyruvate carboxykinase (PEPCK) in liver and an increased expression of the glucose transporter subtype 4 (GLUT 4) in soleus muscle. These effects were also blocked by opioid μ-receptor antagonists. In conclusion, our results suggest that andrographolide may activate α1-ARs to enhance the secretion of β-endorphin which can stimulate the opioid μ-receptors to reduce hepatic gluconeogenesis and to enhance the glucose uptake in soleus muscle, resulting in a decrease of plasma glucose in STZ-diabetic rats. However, the roles of other endogenous opioid peptides or the mixture of several opioid peptides in the activation of opioid μ-receptors associated with the plasma glucose-lowering action of andrographolide, should be considered and need more investigation in the future.
原文英語
頁(從 - 到)529-540
頁數12
期刊Naunyn-Schmiedeberg's Archives of Pharmacology
377
發行號4-6
DOIs
出版狀態已發佈 - 六月 2008

指紋

Endorphins
Type 1 Diabetes Mellitus
Glucose
Streptozocin
Opioid Receptors
Adrenergic Receptors
Opioid Peptides
Narcotic Antagonists
Skeletal Muscle
andrographolide
Phosphoenolpyruvate
Adrenal Medulla
Gluconeogenesis
Facilitative Glucose Transport Proteins
Prazosin
Liver
Adrenalectomy
Knockout Mice

ASJC Scopus subject areas

  • Pharmacology

引用此文

Mediation of β-endorphin in andrographolide-induced plasma glucose-lowering action in type I diabetes-like animals. / Yu, Bu Chin; Chang, Cheng Kuei; Su, Chih Fen; Cheng, Juei Tang.

於: Naunyn-Schmiedeberg's Archives of Pharmacology, 卷 377, 編號 4-6, 06.2008, p. 529-540.

研究成果: 雜誌貢獻文章

@article{fb21b1cdf546430f8dc74183cb25b5a3,
title = "Mediation of β-endorphin in andrographolide-induced plasma glucose-lowering action in type I diabetes-like animals",
abstract = "In the present study, we investigated the mechanism(s) for glucose-lowering action of andrographolide in streptozotocin-induced diabetic rats (STZ-diabetic rats). Andrographolide lowered plasma glucose concentrations in a dose-dependent manner and increased plasma β-endorphin-like immunoreactivity (BER) dose-dependently in diabetic rats. Both of these responses to andrographolide were abolished by the pretreatment of animals with prazosin or N-(2 -(2-cyclopropylmethoxy) ethyl) 5-choro-α-dimethyl-1H- indole-3-thylamine (RS17053) at doses sufficient to block α1- adrenoceptors (ARs). Also, andrographolide enhanced BER release from isolated rat adrenal medulla in a concentration-related manner that could be abolished by α1-ARs antagonists. Bilateral adrenalectomy in STZ-diabetic rats eliminated the activities of andrographolide, including the plasma glucose-lowering effect and the plasma BER-elevating effect. Andrographolide failed to lower plasma glucose in the presence of opioid μ-receptor antagonists and in the opioid μ-receptor knockout diabetic mice. Treatment of STZ-diabetic rats with andrographolide resulted in the reduced expression of phosphoenolpyruvate carboxykinase (PEPCK) in liver and an increased expression of the glucose transporter subtype 4 (GLUT 4) in soleus muscle. These effects were also blocked by opioid μ-receptor antagonists. In conclusion, our results suggest that andrographolide may activate α1-ARs to enhance the secretion of β-endorphin which can stimulate the opioid μ-receptors to reduce hepatic gluconeogenesis and to enhance the glucose uptake in soleus muscle, resulting in a decrease of plasma glucose in STZ-diabetic rats. However, the roles of other endogenous opioid peptides or the mixture of several opioid peptides in the activation of opioid μ-receptors associated with the plasma glucose-lowering action of andrographolide, should be considered and need more investigation in the future.",
keywords = "β-Endorphin, Andrographolide, Opioid μ-receptor, STZ-diabetic rats",
author = "Yu, {Bu Chin} and Chang, {Cheng Kuei} and Su, {Chih Fen} and Cheng, {Juei Tang}",
year = "2008",
month = "6",
doi = "10.1007/s00210-007-0240-0",
language = "English",
volume = "377",
pages = "529--540",
journal = "Naunyn-Schmiedeberg's Archives of Pharmacology",
issn = "0028-1298",
publisher = "Springer Verlag",
number = "4-6",

}

TY - JOUR

T1 - Mediation of β-endorphin in andrographolide-induced plasma glucose-lowering action in type I diabetes-like animals

AU - Yu, Bu Chin

AU - Chang, Cheng Kuei

AU - Su, Chih Fen

AU - Cheng, Juei Tang

PY - 2008/6

Y1 - 2008/6

N2 - In the present study, we investigated the mechanism(s) for glucose-lowering action of andrographolide in streptozotocin-induced diabetic rats (STZ-diabetic rats). Andrographolide lowered plasma glucose concentrations in a dose-dependent manner and increased plasma β-endorphin-like immunoreactivity (BER) dose-dependently in diabetic rats. Both of these responses to andrographolide were abolished by the pretreatment of animals with prazosin or N-(2 -(2-cyclopropylmethoxy) ethyl) 5-choro-α-dimethyl-1H- indole-3-thylamine (RS17053) at doses sufficient to block α1- adrenoceptors (ARs). Also, andrographolide enhanced BER release from isolated rat adrenal medulla in a concentration-related manner that could be abolished by α1-ARs antagonists. Bilateral adrenalectomy in STZ-diabetic rats eliminated the activities of andrographolide, including the plasma glucose-lowering effect and the plasma BER-elevating effect. Andrographolide failed to lower plasma glucose in the presence of opioid μ-receptor antagonists and in the opioid μ-receptor knockout diabetic mice. Treatment of STZ-diabetic rats with andrographolide resulted in the reduced expression of phosphoenolpyruvate carboxykinase (PEPCK) in liver and an increased expression of the glucose transporter subtype 4 (GLUT 4) in soleus muscle. These effects were also blocked by opioid μ-receptor antagonists. In conclusion, our results suggest that andrographolide may activate α1-ARs to enhance the secretion of β-endorphin which can stimulate the opioid μ-receptors to reduce hepatic gluconeogenesis and to enhance the glucose uptake in soleus muscle, resulting in a decrease of plasma glucose in STZ-diabetic rats. However, the roles of other endogenous opioid peptides or the mixture of several opioid peptides in the activation of opioid μ-receptors associated with the plasma glucose-lowering action of andrographolide, should be considered and need more investigation in the future.

AB - In the present study, we investigated the mechanism(s) for glucose-lowering action of andrographolide in streptozotocin-induced diabetic rats (STZ-diabetic rats). Andrographolide lowered plasma glucose concentrations in a dose-dependent manner and increased plasma β-endorphin-like immunoreactivity (BER) dose-dependently in diabetic rats. Both of these responses to andrographolide were abolished by the pretreatment of animals with prazosin or N-(2 -(2-cyclopropylmethoxy) ethyl) 5-choro-α-dimethyl-1H- indole-3-thylamine (RS17053) at doses sufficient to block α1- adrenoceptors (ARs). Also, andrographolide enhanced BER release from isolated rat adrenal medulla in a concentration-related manner that could be abolished by α1-ARs antagonists. Bilateral adrenalectomy in STZ-diabetic rats eliminated the activities of andrographolide, including the plasma glucose-lowering effect and the plasma BER-elevating effect. Andrographolide failed to lower plasma glucose in the presence of opioid μ-receptor antagonists and in the opioid μ-receptor knockout diabetic mice. Treatment of STZ-diabetic rats with andrographolide resulted in the reduced expression of phosphoenolpyruvate carboxykinase (PEPCK) in liver and an increased expression of the glucose transporter subtype 4 (GLUT 4) in soleus muscle. These effects were also blocked by opioid μ-receptor antagonists. In conclusion, our results suggest that andrographolide may activate α1-ARs to enhance the secretion of β-endorphin which can stimulate the opioid μ-receptors to reduce hepatic gluconeogenesis and to enhance the glucose uptake in soleus muscle, resulting in a decrease of plasma glucose in STZ-diabetic rats. However, the roles of other endogenous opioid peptides or the mixture of several opioid peptides in the activation of opioid μ-receptors associated with the plasma glucose-lowering action of andrographolide, should be considered and need more investigation in the future.

KW - β-Endorphin

KW - Andrographolide

KW - Opioid μ-receptor

KW - STZ-diabetic rats

UR - http://www.scopus.com/inward/record.url?scp=45849092979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45849092979&partnerID=8YFLogxK

U2 - 10.1007/s00210-007-0240-0

DO - 10.1007/s00210-007-0240-0

M3 - Article

C2 - 18080810

AN - SCOPUS:45849092979

VL - 377

SP - 529

EP - 540

JO - Naunyn-Schmiedeberg's Archives of Pharmacology

JF - Naunyn-Schmiedeberg's Archives of Pharmacology

SN - 0028-1298

IS - 4-6

ER -